Skip to main content

Table 1 Transition probabilities for initial phase of model (between baseline and 12 months)

From: Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland

   STANDARD OF CARE STRATEGY
Health state at 1-year
HS1 HS2 HS3 HS4 HS5
Health state at baseline HS1 1.00 0.00 0.00 0.00 0.00
HS2 0.25 0.50 0.00 0.25 0.00
HS3 0.00 0.00 1.00 0.00 0.00
HS4 0.00 0.00 1.00 0.00 0.00
HS5 0.00 0.00 0.00 1.00 0.00
   VN STRATEGY
Health state at 1-year
HS1 HS2 HS3 HS4 HS5
Health state at baseline HS1 1.00 0.00 0.00 0.00 0.00
HS2 0.83 0.17 0.00 0.00 0.00
HS3 0.50 0.50 0.00 0.00 0.00
HS4 0.50 0.00 0.25 0.25 0.00
HS5 0.00 0.50 0.00 0.25 0.25
  1. All visual acuity scores measured by logMAR (VA) and visual function (VF) scores measured by sum total degrees, are calculated as the average of both eyes.
  2. HS1, moderate visual impairment (patient either has VA<1 or VF>240; and does not belong to a worse health state); HS2, severe visual impairment (patient either has VA≥1 and VA<1.4, or VF≤240 and VF>144; and does not belong to a worse health state); HS3, profound visual impairment (patient either has VA≥1.4 and VA<1.8, or VF≤144 and VF>48; and does not belong to a worse health state); HS4, counting fingers (patient either has VA≥1.8 and VA<3, or VF≤48; and does not belong to a worse health state); HS5, hand motion, light perception to no light perception (patient has VA≥3, or indications of hand motion, “light perception”, or “no light perception” across both eyes)
  3. BSC best supportive care, TP transition probability, VN voretigene neparvovec